26 results about "Dosing interval" patented technology

The invention discloses an anesthesia depth accurate prediction system and method based on time sequence alignment. The method comprises the steps that a cross-modal joint time sequence characteristic data matrix is acquired and generated; outputting a time sequence alignment feature sample; outputting a future advanced prediction label set; obtaining a first-stage anesthesia depth prediction model; in the first anesthesia depth prediction model training stage, a logic auditing link is introduced, and a self-adaptive online updating model is formed; starting an anti-fact dose simulation module, and outputting a candidate anti-fact administration scheme set; and inputting the candidate anti-factual administration scheme set into a dynamic security constraint optimizer, rejecting non-compliant schemes by the dynamic security constraint optimizer according to single maximum dose limitation, single additional dose and administration times in a minimum administration interval, and outputting an optimal administration suggestion. According to the method, combined classification judgment is carried out on the anesthesia state grade and the change trend of each prediction step, and the sensitivity of clinical risk identification and abnormal situation early warning is effectively improved.

The invention discloses a patient historical state-based anesthetic dose simulation evaluation system, which is characterized by comprising a multi-source data integration and preoperative physiological feature quantification layer, a dose effect relationship simulation layer and a risk evaluation and recommendation output layer. The method has the following advantages and effects that the personalized pharmacokinetics-pharmacodynamics model is constructed by integrating multi-source historical data of a patient, vital sign change tracks under different anesthetic doses are simulated, the recommended dose interval is generated based on multi-objective optimization, the change from experience dependence to accurate quantification is realized, and the accuracy of the recommended dose interval is improved. The problem of inaccurate anesthetic dosage prediction caused by individual differences is effectively solved, and the safety and effectiveness of an anesthesia scheme are remarkably improved.

The application discloses a complex long-acting preparation steady-state pharmacokinetics extrapolation equivalence prediction method, relates to the steady-state bioequivalence technical field, and comprises the following steps: collecting and unifying concentration-time, a drug administration scheme and a covariate, generating a standardized time, an event marker code and a covariate dictionary, setting a deletion weight and a population alignment weight; setting a candidate structure based on population pharmacokinetics, estimating a model and a covariate effect through a quality threshold determination with a weight; constructing a virtual population and performing multiple drug administration simulation to determine the reaching of stability according to the relative change of consecutive two trough concentrations, generating a peak-trough sampling time window; performing non-compartment analysis in the steady-state interval, calculating a dosing interval area, a steady-state peak value and a steady-state trough value, calculating a geometric mean ratio and a confidence interval of two preparations, carrying out efficacy-sample size linkage, and outputting a recommended design; the method can reduce the test burden, shorten the cycle and improve the decision transparency.

The present invention relates to drugs, dosage regimens, dosing intervals, and methods of administration for treating antibody-mediated rejection using an effective amount of a drug targeting Blys and / or APRIL. The result shows that the provided effective dose of the drug targeting Blys and / or APRIL shows good safety and treatment effect in the process of preventing, treating or relieving antibody-mediated rejection in patients who are about to accept, are receiving or have accepted entity organ transplantation.

A mesh network medication coordination system enables communication between intelligent injection devices, monitoring systems, patient devices, or healthcare provider devices to prevent adverse drug interactions in hospital settings. The system includes mesh network infrastructure supporting multiple networked devices, dosage measurement devices that directly measure or infer dosage administration including injection completion detection, medication volume measurement, administration timing data, or patient biometric responses, or a coordination module that coordinates medication administration timing across multiple devices. The system features drug interaction analysis capabilities, real-time monitoring of patient vital signs and medication effectiveness, alert generation for potential interactions and dosing conflicts, or data synchronization across all networked devices. This integrated approach optimizes dosing intervals, prevents conflicting medication schedules, synchronizes administration events, or maintains consistent medication administration data across the mesh network to enhance patient safety and treatment efficacy.

A drug, dosage regimen, administration interval, and mode of administration for the treatment of ANCA-associated vasculitis (AAV) using an effective amount of a drug targeting Blys and / or APRIL. The result shows that the provided effective dose of the drug targeting Blys and / or APRIL shows good safety and treatment effect in the process of treating or relieving ANCA-related vasculitis patients.

The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

The invention discloses a method for separating quartz and feldspar by flotation, which comprises the following steps of: crushing, finely grinding and screening quartz ore, adding the quartz ore into a flotation tank, firstly adding a proper amount of water, stirring and mixing pulp, adding diluted hydrochloric acid or sodium hydroxide solution to adjust the pH value of the pulp to be alkaline, and filtering to obtain filtrate; and then a feldspar inhibitor ethylene diamine tetra (methylene sodium phosphate) and a collecting agent octadecyl trimethyl ammonium chloride are added, the dosing interval is 3 min, and finally foam and tank bottom products are obtained after air inflation flotation and foam scraping. Single ethylene diamine tetra (methylene sodium phosphate) is adopted as a feldspar inhibitor, the defects that an existing inhibitor is prone to causing poor selectivity of a collecting agent, large using amount, complex using process, large beneficiation wastewater treatment difficulty and the like are overcome, and excellent environment friendliness is achieved; according to the invention, sodium ethylene diamine tetra (methylene phosphate) and octadecyl trimethyl ammonium chloride are cooperatively used, so that the method has the advantages of simple reagent system, convenience in use process, alkaline ore pulp pH, outstanding separation effect and the like. The method effectively solves the industrial problems of low quartz feldspar separation efficiency, poor selectivity, high environmental protection pressure and the like under the current fluoride-free and acid-free system.

The present disclosure relates to treatment regimens for the treatment of multiple sclerosis (MS). These methods include subcutaneous administration of anti-CD20 antibodies and provide efficacy and safety with extended subcutaneous administration intervals.

The present invention relates to a drug for treating or alleviating antiphospholipid syndrome by using an effective amount of the drug targeting Blys and / or APRIL, a dosage regimen, an administration interval and an administration mode. The results show that the provided effective amount of the drug targeting Blys and / or APRIL exhibits good safety and excellent therapeutic effect during the treatment of alleviation of patients with antiphospholipid syndrome.

Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a PRAME positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 5-40 μg; (b) at least one second dose in the range of from 15-80 μg; and then (c) at least one third dose in the range of from 60-400 μg, wherein the second dose is higher than the first dose and the third dose is higher than the second dose, and wherein doses are administered every 6-8 days.

The present disclosure relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by the present disclosure shows relatively good clinical curative effect and good safety in the process of treating a patient with membranous nephropathy.

The present invention relates to the field of therapy. More particularly, the present invention relates to therapeutic methods in which effector components are administered that require cellular uptake to become effective and / or exert their effect via intracellular (molecular) targets, such as but not limited to nucleic acid or oligonucleotide therapeutic agents. The present invention provides modes that extend the duration of the effect of the effector component and / or extend the interval of administration of the effector component and / or reduce the frequency of administration of the effector component and / or cause a (delayed) enhancement of the effect of the effector component.

The present invention relates to technology for delivering a peptide drug and, specifically, to a pharmaceutical composition comprising albumin and a peptide comprising a fatty acid chain. Using the composition according to the present invention prevents a rapid increase in initial blood concentration compared to existing peptide drugs and minimizes blood concentration deviation, and thus can significantly reduce side effects compared to existing peptide derivatives. In addition, the dosing interval is extended, thus enhancing patient convenience.

To provide a method of administering a therapeutic dose of a bispecific T cell engaging molecule for the treatment of cancer.SOLUTION: The present invention relates to methods of administering a therapeutic dose of a bispecific T cell engaging molecule for the treatment of cancer in a patient. The method of administration reduces the incidence and / or severity of adverse events such as cytokine release syndrome and involves administering to a patient a priming dose of a bispecific T cell engaging molecule by continuous intravenous infusion over a period of several days, followed by administration of a therapeutic dose of the bispecific T cell engaging molecule by bolus intravenous infusion at a dosing interval of at least one week. In a particular embodiment of the method of the invention, the initial cycle comprises administering the priming doses of the bispecific T cell engaging molecule by continuous intravenous (IV) infusion (also referred to as extended IV infusion (eIV)) over a period of at least 1 day, such as 1 to 7 days.SELECTED DRAWING: None

The invention discloses a Rurugolil long-acting preparation composition as well as a preparation method and application thereof. The composition comprises an active medicine and at least one suspending aid. The Rurugolil long-acting preparation composition has an excellent slow-release effect, the administration interval can be prolonged to 7-90 days per time from 1 day per time, and the bioavailability, the compliance and the safety of a patient are remarkably improved. The pharmaceutical composition disclosed by the invention has the advantages of high preparation stability, simple prescription, controllable preparation process and capability of realizing industrial production amplification.

We provide a combination containing meloxicam and rizatriptan. [Solution] A composition is disclosed comprising an NSAID such as meloxicam and / or rizatriptan in combination with cyclodextrin and / or carbonate or bicarbonate. These compositions can be administered orally to improve the bioavailability or pharmacokinetics of NSAIDs for the treatment of pain such as migraines, arthritis, and other conditions. Also provided is a method for treating pain such as migraines, comprising administering meloxicam and rizatriptan to a person suffering from pain such as migraines. These methods may be particularly useful when administering meloxicam and rizatriptan while a person is suffering from an acute migraine attack or aura. In some embodiments, the combination of meloxicam and rizatriptan is used, with meloxicam being T max It may be administered so that the time interval is 3 hours or less.

Disclosed in the present invention are a long-acting formulation composition of Relugolix, a preparation method therefor, and use thereof. The composition comprises an active drug and at least one suspending agent. The long-acting formulation composition of Relugolix of the present invention has an excellent sustained-release effect, can prolong the administration interval from 1 day / time to 7 days to 90 days / time, and significantly improves the bioavailability, compliance, and safety of patients. The pharmaceutical composition of the present invention has the advantages of high formulation stability, simple prescription, controllable preparation process, and scale-up capability for industrial production.

This invention relates to a drug for treating ANCA-associated vasculitis (AAV) using an effective dose of the drug, administration regimen, administration interval, and dosage form targeting BlyS and / or APRIL. The provided effective dose of the drug targeting BlyS and / or APRIL has been demonstrated to exhibit good safety and therapeutic efficacy in the treatment or relief of patients with ANCA-associated vasculitis.

The invention discloses a complex long-acting preparation steady-state pharmacokinetic extrapolation equivalence prediction method, and relates to the technical field of steady-state bioequivalence, and the method comprises the steps: collecting and unifying concentration-time, administration schemes and covariables, generating standardized time, event identification codes and a covariable dictionary, and setting a deletion weight and a crowd alignment weight; setting a candidate structure based on group pharmacokinetics, and determining a model and a covariant effect through a weight estimation quality threshold; constructing a virtual crowd, carrying out multiple times of drug administration simulation, judging that the stability is achieved according to two continuous relative changes of valley concentrations, and generating a peak-valley sampling time window; carrying out non-atrioventricular analysis in the steady-state interval, calculating an administration interval area, a steady-state peak value and a steady-state valley value, calculating a geometric mean ratio and a confidence interval for the two preparations, carrying out efficacy-sample size linkage, and outputting a recommended design; the method can reduce the test burden, shorten the period and improve the decision transparency.

In the treatment of patients with tumors (especially malignant tumors), the substances phenoxythiamine (B-OT) and / or oxothiamine (OT) are administered as active ingredients concurrently with ongoing radionuclide therapy (RNT) (particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT)). B-OT and / or OT administration is cyclical, meaning that dosing phases of B-OT and / or OT (“B-OT / OT dosing cycles”) alternate with treatment intervals (dosing intervals). During each B-OT / OT dosing cycle, B-OT and / or OT are administered at a predetermined dose (mg / kg patient body weight) for one or more consecutive days. This is followed by a treatment interval during which neither B-OT nor OT is administered, before the next B-OT / OT dosing cycle begins.

Offering extended interval administration of natalizumab. [Solution] Provided herein are methods for reducing the risk of developing progressive multifocal leukemia in patients receiving natalizumab therapy by switching to an extended interval dosing (EID) schedule, in some embodiments. In one embodiment, a method is provided for improving the safety of chronic natalizumab therapy, the method comprising determining whether a patient has at least one risk factor for PML, and, in the presence of at least one risk factor, administering natalizumab to the patient on an extended interval dosing (EID) schedule with intervals of at least 5 weeks.

The efficacy of a dosing regimen can be altered, and preferably improved, by fractionating the doses. Here fractionating the doses can be regarded as taking a single conventional dose and splitting that dose into two or more dose-fractions delivered at relatively short time intervals, where the dose-fractions add up to the same total dose as the conventional dose. In cases where dose fractionation increases the therapeutic effect, this can result in a greater therapeutic effect from a smaller total dose when the doses are fractionated. This effect has been demonstrated in an ophthalmic application, but is expected to be more generally applicable.

This invention relates to the field of medical information management technology, specifically to an intelligent verification method and system for vaccine administration processes. In this invention, isolated operation logs during the vaccination process are reconstructed into a complete sequence of recipient vaccination behaviors based on their inherent temporal correlation and the homology of the executing entities. A Hidden Markov Model is then used to perform in-depth analysis of this sequence, inferring the underlying vaccination stage states that conform to clinical logic from the observed specific behaviors. This elevates verification from static data checking to a dynamic process review. Furthermore, the inferred actual stage sequence is rigorously compared with the standardized process in three dimensions: stage completeness, sequential accuracy, and dose interval. Innovatively, a probability confidence level is calculated for any identified process deviations, achieving a quantitative assessment of abnormal behavior.

The present invention relates to a composition for treating joint diseases and a preparation method therefor and, more specifically, to a composition comprising a cross-linked hyaluronic acid hydrogel obtained by a cross-linking reaction between hyaluronic acid or a pharmaceutically acceptable salt thereof and an alkylene diamine cross-linking agent, and a preparation method therefor. The composition has a storage modulus (G', 2.5 Hz, 25° C) of 250-850 Pa, has a degree of cross-linking (CrD; number of cross-linking agents bound to both sides / number of hyaluronic acid units) of less than 5 mol %, and exhibits an effect of alleviating symptoms of joint diseases for a period of 3 months or longer when administered once as an injectable formulation to a patient. The composition has a low degree of crosslinking that allows flexible adjustment of the dosing interval while maintaining high biocompatibility, in vivo persistence, and a clinically meaningful storage modulus, thereby reducing patient burden caused by frequent administration and being expected to provide an excellent clinical effect of alleviating joint disease symptoms for three months or longer.